AstraZeneca announces "positive" high-level results from a planned interim analysis of the AEGEAN Phase III, placebo- controlled trial showed that treatment with AstraZeneca’s Imfinzi in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery demonstrated a statistically significant and clinically meaningful improvement in event-free survival, or EFS, versus neoadjuvant chemotherapy alone followed by surgery for patients with resectable early-stage non-small cell lung cancer, or NSCLC. Results from the final pathologic complete response and major pathologic response analyses were consistent with previously announced positive results. The trial will continue as planned to assess key secondary endpoints including disease-free survival, or DFS, and overall survival, or OS, the company announced.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AZN:
- Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs
- Mineralys Therapeutics initiated with an Outperform at Evercore ISI
- AstraZeneca, Daiichi Sankyo announce Enhertu met the prespecified target for ORR
- AstraZeneca says Enhertu met prespecified criteria for ORR in DESTINY-PanTumor02
- AstraZeneca says FDA to convene AdCom meeting on sNDA for Lynparza in mCRPC
